iPS Cells & Regenerative Medicine– category –
-
Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP
Cellistic Belgium Overview Cellistic is offering specialized Contract Development and Manufacturing Organization (CDMO) services tailored for iPSC-derived cell therapies. Leveraging bioreactor-based, GMP-compliant processes, the company ... -
Taiwan’s ITRI Establishes Highly Stable iPSC-Based MSC and Exosome Manufacturing Platform to Advance Regenerative Medicine
Industrial Technology Research Institute (ITRI) Taiwan Overview Taiwan's Industrial Technology Research Institute (ITRI) has established a highly stable iPSC-based mesenchymal stem cell (MSC) and exosome manufacturing platform. This plat... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
ICR Unveils New ‘DOSET’ Statistical Approach to Optimize Early-Stage Cancer Clinical Trials for CAR-T and Advanced Therapies
The Institute of Cancer Research, London UK Overview Researchers at The Institute of Cancer Research (ICR), London, have developed 'DOSET' (Dose Optimization with Simultaneous Efficacy and Toxicity), a new statistical approach to identif... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci... -
Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Morningstar USA Overview Porton Advanced, a CDMO, announced that its umbilical cord-derived mesenchymal stem cell (UC-MSC) cell bank for exosome manufacturing has received Drug Master File (DMF) acceptance from the U.S. FDA. This accepta... -
Fate Therapeutics to Announce Preliminary Clinical Data for iPSC-Derived CAR T-Cell FT819 for Systemic Sclerosis at ISSCR 2026
GlobeNewswire USA Overview Fate Therapeutics announced it will present preliminary clinical data for its iPSC-derived 'off-the-shelf' CAR T-cell candidate FT819 for systemic sclerosis (SSc) at the International Society for Stem Cell Rese... -
Scribe Therapeutics Files for Nasdaq IPO, Advancing CRISPR-Based Cardiovascular Disease Platform STX-1150 for Hypercholesterolemia
Endpoints News USA Overview Scribe Therapeutics, co-founded by Nobel laureate Dr. Jennifer Doudna, has filed for an initial public offering (IPO) on Nasdaq. This move signals a crucial strategy for the company to expand its CRISPR-based ... -
Auxilium Biotechnologies Achieves Historic First with 3D Bioprinting of Kidney and Liver Tissue on International Space Station
Las Vegas Sun USA Overview Auxilium Biotechnologies has achieved a groundbreaking feat in space-based 3D bioprinting, successfully printing kidney and liver tissue for the first time aboard the International Space Station (ISS). This acc... -
MeiraGTx Secures Up To $400 Million From Oberland Capital to Support Commercialization of Two Gene Therapies
Fierce Biotech USA Overview MeiraGTx has finalized a funding agreement with Oberland Capital totaling up to $400 million. This capital will support the commercialization of the company's two late-stage gene therapy candidates: bota-vec f...
